

Product Name : CYC065

Synonyms : CYC-065; CYC 065


Cat No. : M10291

CAS Number : 1070790-89-4

Molecular Formula : C₂₁H₃₁N₇O

Formula Weight : 397.53

Chemical Name : (2R,3S)-3-[[6-[(4,6-dimethylpyridin-3-yl)methylamino]-9-propan-2-yl]purin-2-yl]amino]pentan-2-ol



Description : CYC065 is a derivative of seliciclib and second generation CDK inhibitor that is mainly active on CDK2/5/9; demonstrates cytotoxicity both in MM cell lines sensitive as well as resistant to conventional chemotherapy with IC₅₀ of 0.06-2 μM; blocks cells in the G1 phase and inhibits cell growth specifically in CCNE1-overexpressing USCs; significantly reduces tumour growth in xenografts derived from CCNE1-amplified USCs, shows synergistic effect in vitro and in vivo combined with Taselisib .Brain Cancer Phase 1 Clinical

Pathway : Angiogenesis

Target : CDK

Receptor : CDK

Solubility : DMSO : ≥ 100 mg/mL 251.56 mM

SMILES : CCCC(C(C)O)NC1=NC(=C2C(=N1)N(C(=N2)C(C)C)NCC3=CN=C(C=C3C)C

Storage : (-20°C)

Stability : ≥ 2 years

Reference :

1. Cocco E, et al. Br J Cancer. 2016 Jul 26;115(3):303-11. | 2. Kawakami M, et al. J Natl Cancer Inst. 2017 Jun 1;109(6). | 3. Thomas AL, et al. Cell Cycle. 2017 Aug 3;16(15):1453-1464. | 4. Rao SS, et al. Oncotarget. 2017 Aug 10;8(48):83925-83939.